User:Gmoren5/Opportunistic infections: Difference between revisions
→Article Draft: Talk discussion added |
→Article body: Started on the edits |
||
| Line 16: | Line 16: | ||
=== Lead === |
=== Lead === |
||
Prophylactic medications |
|||
=== Article body === |
=== Article body === |
||
{| class="wikitable" |
|||
|+ |
|||
!Opportunistic infections |
|||
!Indication(s) for prophylactic medications |
|||
!Preferred agent(s) or (''alternative agent'') |
|||
!When to discontinue agent(s) |
|||
|- |
|||
|Mycobacterium tuberculosis |
|||
|Upon diagnosis of HIV and regardless of the CD4 count, any positive screening, or prior medical history of Mycobacterium tuberculosis. |
|||
|Rifampicin or (''Rifabutin'') |
|||
Isoniazid |
|||
Pyridoxine |
|||
Pyrazinamide |
|||
Ethambutol |
|||
|These agents will discontinue after two months. Rifampicin or (''rifabutin''), isoniazid, and pyridoxine will continue for at least four more months, depending on clinical presentation. |
|||
|- |
|||
|Pneumocystis jiroveci |
|||
|CD4 count is less than 200 cells/mm<sup>3</sup> or less than 14%. The person has documented medical history of recurrent oropharyngeal candidiasis. |
|||
|Trimethoprim-sulfamethoxazole |
|||
(''Dapsone'') |
|||
(''Atovaquone'') |
|||
(''Pentamidine'') |
|||
|These agent(s) will discontinue once the CD4 count is above 200 cells/mm<sup>3</sup> and HIV viral load is undetectable for at least three months while taking antiretroviral therapy. |
|||
|- |
|||
| |
|||
| |
|||
| |
|||
| |
|||
|} |
|||
=== References === |
=== References === |
||
<nowiki>https://www.eacsociety.org/media/final2021eacsguidelinesv11.0_oct2021.pdf</nowiki> --> EU society guidelines for opportunistic infections, last updated in 2021 |
|||
<nowiki>https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/adult-adolescent-oi/guidelines-adult-adolescent-oi.pdf</nowiki> --> CDC and NIH guidelines for opportunistic infections, updated regularly |
|||
<nowiki>https://www.ncbi.nlm.nih.gov/books/NBK567851/pdf/Bookshelf_NBK567851.pdf</nowiki> --> New York clinical guideline for HIV care, updated in 2021 |
|||
[[Category:Wikipedia Student Program]] |
[[Category:Wikipedia Student Program]] |
||
Revision as of 17:10, 8 February 2023
 | This is the sandbox page where you will draft your initial Wikipedia contribution.
If you're starting a new article, you can develop it here until it's ready to go live. If you're working on improvements to an existing article, copy only one section at a time of the article to this sandbox to work on, and be sure to use an edit summary linking to the article you copied from. Do not copy over the entire article. You can find additional instructions here. Remember to save your work regularly using the "Publish page" button. (It just means 'save'; it will still be in the sandbox.) You can add bold formatting to your additions to differentiate them from existing content. |
Article Draft
Talk:
Hello, I am a fourth-year medical student participating in the WikiMed course at my university. I’m excited to be able to participate in this article and would welcome any suggestions or advice for my following edits. I am mainly focused on the prophylactic medication section. I want to add other infections we should be aware of when starting prophylactic medications. I also want to add more information on the indication sections, as CD4 count is not the only indication to start prophylactic medication. I want to add a new section discussing when it is appropriate to discontinue the medication. And finally, I want to update and add alternative medications when suggesting the agent.
Below is the bibliography, where I will be referring to the information. Thank you in advance for your suggestions and advice.
https://www.eacsociety.org/media/final2021eacsguidelinesv11.0_oct2021.pdf --> EU society guidelines for opportunistic infections, last updated in 2021
https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/adult-adolescent-oi/guidelines-adult-adolescent-oi.pdf --> CDC and NIH guidelines for opportunistic infections, updated regularly
https://www.ncbi.nlm.nih.gov/books/NBK567851/pdf/Bookshelf_NBK567851.pdf --> New York clinical guideline for HIV care, updated in 2021
Lead
Prophylactic medications
Article body
| Opportunistic infections | Indication(s) for prophylactic medications | Preferred agent(s) or (alternative agent) | When to discontinue agent(s) |
|---|---|---|---|
| Mycobacterium tuberculosis | Upon diagnosis of HIV and regardless of the CD4 count, any positive screening, or prior medical history of Mycobacterium tuberculosis. | Rifampicin or (Rifabutin)
Isoniazid Pyridoxine Pyrazinamide Ethambutol |
These agents will discontinue after two months. Rifampicin or (rifabutin), isoniazid, and pyridoxine will continue for at least four more months, depending on clinical presentation. |
| Pneumocystis jiroveci | CD4 count is less than 200 cells/mm3 or less than 14%. The person has documented medical history of recurrent oropharyngeal candidiasis. | Trimethoprim-sulfamethoxazole
(Dapsone) (Atovaquone) (Pentamidine) |
These agent(s) will discontinue once the CD4 count is above 200 cells/mm3 and HIV viral load is undetectable for at least three months while taking antiretroviral therapy. |
References
https://www.eacsociety.org/media/final2021eacsguidelinesv11.0_oct2021.pdf --> EU society guidelines for opportunistic infections, last updated in 2021
https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/adult-adolescent-oi/guidelines-adult-adolescent-oi.pdf --> CDC and NIH guidelines for opportunistic infections, updated regularly
https://www.ncbi.nlm.nih.gov/books/NBK567851/pdf/Bookshelf_NBK567851.pdf --> New York clinical guideline for HIV care, updated in 2021